Fig. 8

The Fiduxosin and SB206553 APE1/NPM1 interaction-inhibitors sensitize only HCC70 cells to platinum compounds treatment. Histograms show the effect of co-treatments with CDDP (a, c, d) or CBDCA (b-e, f) and APE1/NPM1 inhibitors including Fiduxosin (a, b, d, e) and SB206553 (c), on HCC70 cells viability. Analysis was carried on for 48 h of treatment (a,b,c) or 72 h of treatment (d, e). Values express the mean viability ± SD from at least three independent replicates. Each value is normalized to the untreated condition. *p < 0.05, **p < 0.001, ***p < 0.0001. A Bliss analysis, performed on these data, confirmed the existence of an additive effect of the APE1/NPM1 inhibitors on HCC70 cell line (data not shown)